The value of biomarkers in cerebrospinal fluid in acute spinal cord injury as predictor of outcome.

The value of biomarkers in cerebrospinal fluid in acute spinal cord injury as predictor of outcome. - SPinal cord Diagnostic Improvements (SPIDI) study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34689

Enrollment

Registered

2010-08-03

Start date

2011-04-13

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal cord injury traumatic myelopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Blunt spinal cord injury (Neurological level of injury C2-Th10) Neurological deficit Primarily refererred Glasgow Coma Scale >= 10 (E4+V6)

Exclusion criteria

Exclusion criteria: penetrating spinal cord injury normal neurologic examination non-traumatic spinal cord injury traumatic brain injury pre-existent neurological disorder

Design outcomes

Primary

Measure	Time frame
1. The concentrations of Neuron Specific Enolase, Glial Fibrillary Acidic Protein, S-100ß, Neurofilament Protein, Tau and Myelin Basic Protein in CSF in patients with SCI. 2. Evaluation of the ASIA classification system and SCIM of all patients at different times 3. The relation between the concentrations of Neuron Specific Enolase, Glial Fibrillary Acidic Protein, S-100ß, Neurofilament Protein, Tau and Myelin Basic Protein in CSF and the ASIA impairment scale after 12 months in SCI patients	—

Measure

Time frame

1. The concentrations of Neuron Specific Enolase, Glial Fibrillary Acidic Protein, S-100ß, Neurofilament Protein, Tau and Myelin Basic Protein in CSF in patients with SCI. 2. Evaluation of the ASIA classification system and SCIM of all patients at different times 3. The relation between the concentrations of Neuron Specific Enolase, Glial Fibrillary Acidic Protein, S-100ß, Neurofilament Protein, Tau and Myelin Basic Protein in CSF and the ASIA impairment scale after 12 months in SCI patients

—

Secondary

Measure	Time frame
is not applicable	—

Countries

Netherlands

Outcome results